Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity : glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084124" target="_blank" >RIV/00023001:_____/23:00084124 - isvavai.cz</a>
Result on the web
<a href="https://diabetesjournals.org/care/article/46/4/e89/148378/Endoscopic-Duodenal-Jejunal-Bypass-Liner-Treatment" target="_blank" >https://diabetesjournals.org/care/article/46/4/e89/148378/Endoscopic-Duodenal-Jejunal-Bypass-Liner-Treatment</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2337/dc22-1952" target="_blank" >10.2337/dc22-1952</a>
Alternative languages
Result language
angličtina
Original language name
Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity : glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide
Original language description
There is a worldwide pandemic of type 2 diabetes (T2D) and obesity. In clinical practice, many patients with obesity have poor glycemic management despite diet and lifestyle advice and maximal medications. In this situation, Roux-en-Y gastric bypass is highly effective, and increased use of bariatric surgery has been recommended. Nevertheless, it is an invasive and irreversible surgical procedure. EndoBarrier (GI Dynamics, Boston, MA), also known as duodenal-jejunal bypass liner, is a 60-cm impermeable fluoropolymer sleeve that is implanted endoscopically into the upper part of the small intestine, left in place for up to 1 year, and then removed endoscopically. The duodenal-jejunal bypass liner was developed to mimic the proposed small-bowel mechanisms of Roux-en-Y gastric bypass (2–4) while being less invasive. In Europe in 2017, approval for use (certificate of Conformité Européenne, or CE mark) of EndoBarrier was not renewed for reasons that are not entirely clear. As over 3,000 patients have been treated with EndoBarrier worldwide, during 2017, an independent, secure, online registry was established by the Association of British Clinical Diabetologists (ABCD) for the collection of safety and efficacy data of EndoBarrier-treated patients worldwide.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes care
ISSN
0149-5992
e-ISSN
1935-5548
Volume of the periodical
46
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
3
Pages from-to
"e89"-"e91"
UT code for WoS article
001046687500001
EID of the result in the Scopus database
2-s2.0-85151043009